KR930700468A - 신규의 약학적 활성을 지닌 카테콜 유도체 - Google Patents

신규의 약학적 활성을 지닌 카테콜 유도체

Info

Publication number
KR930700468A
KR930700468A KR1019920702604A KR920702604A KR930700468A KR 930700468 A KR930700468 A KR 930700468A KR 1019920702604 A KR1019920702604 A KR 1019920702604A KR 920702604 A KR920702604 A KR 920702604A KR 930700468 A KR930700468 A KR 930700468A
Authority
KR
South Korea
Prior art keywords
compound
formula
dihydroxy
methylidene
group
Prior art date
Application number
KR1019920702604A
Other languages
English (en)
Other versions
KR100207144B1 (en
Inventor
레이조 배크스트됨
에르키 혼카넨
인게-브리트 린덴
에르키 니시넨
아이노 피퓨리
펜티 포토
타피오 코르코라이넨
Original Assignee
펜티 포토, 라이자 맨티라
오리온 위티머 오위
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909009565A external-priority patent/GB9009565D0/en
Priority claimed from GB919101563A external-priority patent/GB9101563D0/en
Application filed by 펜티 포토, 라이자 맨티라, 오리온 위티머 오위 filed Critical 펜티 포토, 라이자 맨티라
Publication of KR930700468A publication Critical patent/KR930700468A/ko
Application granted granted Critical
Publication of KR100207144B1 publication Critical patent/KR100207144B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C07D239/40—One sulfur atom as doubly bound sulfur atom or as unsubstituted mercapto radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음.

Description

신규의 약학적 활성을 지닌 카테콜 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (43)

  1. 일반식(I)의 화합물 또는 약학적으로 적용가능한 그이 염 또는 에스테르.
  3. 상기식중, R1은 니트로, 할로겐 또는 시아노기와 같은 전기적으로 음성인 치환체이며, R2는
  5. [상기식중, X1,X2,Y 및 Z는 독립적으로 산소, 황 또는 NR(식중, R은 수소알킬, 시클로알킬, 아랄킬 또는 아릴기이다)을 나타낸다.]로 부터 선택된 그룹이다.
  6. 제1항에 있어서, R1이 시아노기인 화합물.
  7. 제1항에 있어서, R1이 니트로기인 화합물.
  8. 제1항에 있어서, R1이 할로겐인 화합물.
  9. 제1항 내지 4항중 어느 한 항에 있어서, 구조식(I) 화합물에서 R2가 구조식(Ia)그룹인 화합물.
  11. 상기식중, X1및 X2는 모두 NR(식중, R은 수소 또는 알킬이다.)을 나타내며, Y는 산소 또는 황을 나타내며 Z도 산소 또는 황이다.
  12. 제5항에 있어서, 구조식(I)의 화합물이 4-〔(3,4-디히드록시-5-니트로페닐)메틸리덴〕-2-티옥소이미다졸리딘-5-온, 4-〔(3,4-디히드록시-5-클로로페닐)메틸리덴]-2-티옥소이미다졸리딘-5-온 및 4-〔(3,4-디히드록시-5-니트로페닐)메틸리덴〕-2,5-이미다졸리딘디온 중에서 선택된 화합물.
  13. 4-〔(3,4-디히드록시-5-시아노페닐)메틸리덴〕-2-티옥소이미다졸리딘-5-온 또는 약학적으로 적용 가능한 그의 염 또는 에스테르.
  14. 제1항 내지 4항중 어느 한 항에 있어서, 구조식(I) 화합물에서 R2가 구조식 (Ia)인 화합물.
  16. 상기식중, X1,Y 및 Z는 각각 독립적으로 산소 또는 황을 NR(식중, R은 수소 또는알킬이다.)을 나타낸다.
  17. 제8항에 있어서, 구조식(I)의 화합물이 5-[(3,4-디히드록시-5-니트로페닐)메틸리덴〕-2-티옥소티아졸리딘-4-온, 5-〔(3,4-디히드록시-5-니트로페닐)메틸리덴]-3-메틸-2-티옥소티아졸리딘-4-온, 5-[(3,4-디히드록시-5-니트로페닐)메틸리덴]-티아졸리딘-2,4-디온, 5-[(3,4-디히드록시-5-클로로페닐)메틸리덴]-티아졸리딘-2,4-디온, 5-[(3,4-디히드록시-5-니트로페닐)메틸리덴]-4-티옥소-2-옥사졸리딘 및 5-[(3,4-디히드록시-5-니트로페닐)메틸리덴]-4-티옥소티아졸리딘-2-온 중에서 선택
  18. 5-[(3,4-디히드록시-5-시아노페닐)메틸리덴]-2-티옥소티아졸리딘-4-온 또는약학적으로 적용 가능한 그의 염 또는 에스테르.
  19. 제1항 내지 4항중 어느 한 항에 있어서, 구조식(I) 화합물에서 R2가 구조식(Ia)그룹인 화합물.
  21. 상기식중, X, 및 Z는 독립적으로 산소 또는 황이며 Y 및 X2는 NR(식중, 은 수소이다.)을 나타낸다.
  22. 5-[(3,4-디히드록시-5-니트로페닐)메틸리덴]-2-아미노티아졸리딘-4-온 또는 약학적으로 적용가능한 그의 염 또는 에스테르.
  23. 제1항 내지 4항중 어느 한 항에 있어서, 구조식(I) 화합물에서 R2가 (Ia) 그룹이며, 그중 R2가
  25. [상기식중, Y는 산소 또는 황이며, X1은 NR(식중, R은 수소 또는 알킬이다.)을 나타낸다.]인 화합물.
  26. 제13항에 있어서, Y가 산소인 화합물.
  27. 5-[(3,4-디히드록시-5-니트로페닐)메틸리덴]-2,4,6(1H,3H,5h)-피리미딘트리온 또는 약학적으로 적용가능한 그의 염 또는 에스테르.
  28. 5-[(3,4,-디히드록시-5-니트로페닐)메틸]-(1H,3H,5H)-피리미딘-2,4,6-트리온 또는 약학적으로 적용가능한 그이 염 또는 에스테르.
  29. 제1항 낸지 16항에 있어서, 외과적 수술, 치료, 진단등의 의학적 방법에 사용되는 화합물.
  30. 제1항 내지 16항의 화합물과 약학적으로 적용가능한 담체 또는 희석제를 함유하는 약학적 조성물.
  31. 본 발명에서 사용하는 약제의 제조 및 지방 과산화에 의한 조직 손상의 치료를 위한 제1항 내지 16항의 화합물의 용도.
  32. 제19항에 있어서, 치료 또는 예방을 해야할 조직 손상의 상태가, 심장 질환, 류마티스 관절염, 종양, 염증 질환, 이식 부작용, 저혈, 노화인 화합물의 용도.
  33. 제1-16항의 화합물의 효과적인 양을 그 대상에 복용시키는 지방 과산화에 의한 조직 손상의 예방 및 치료방법.
  34. 구조식(Ⅱ) 화합물의 알데히드기를 활성 메틸렌기를 가진 구조식 (Ⅲ)또는 (Ⅳ)화합물과 축합시켜, R2가 구조식(Ia) 기인 구조식(Ⅰ)화합물을 얻은후, 구조식(Ⅰa) 기의 탄소 -탄소 이중결합을 환원시켜 R2가 본 발명의 구조식(Ib)기 인 구조식(Ⅰ) 화합물을 생성시키는 공정으로 행해지는 구조식(Ⅰ)화합물의 제조방법.
  36. 상기식중, R1은 니트로, 할로겐, 시아노기와 같은 전기적으로 음성인 치환체이며, R2는
  38. 상기식중,X1,X2,및 Z는 각각 독립적으로 산소, 황 또는 NR(식중,R은 수소, 알킬,시클로알킬, 아랄킬 또는 아릴기이다.)을 나타낸다.
  40. 상기식중, R1은 상기한바와 같다.
  42. 상기식중,X1,X2,Y및 Z는 상기한 바와 같다.
  43. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920702604A 1990-04-27 1992-10-21 New pharmacologically active catechol derivatives KR100207144B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB909009565A GB9009565D0 (en) 1990-04-27 1990-04-27 New pharmacologically active catechol derivatives
GB9101563.6 1991-01-24
GB919101563A GB9101563D0 (en) 1991-01-24 1991-01-24 New pharmacologically active catechol derivatives
GB9009565.4 1991-01-24
PCT/FI1991/000124 WO1991017151A1 (en) 1990-04-27 1991-04-26 New pharmacologically active catechol derivatives

Publications (2)

Publication Number Publication Date
KR930700468A true KR930700468A (ko) 1993-03-15
KR100207144B1 KR100207144B1 (en) 1999-07-15

Family

ID=26297011

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920702604A KR100207144B1 (en) 1990-04-27 1992-10-21 New pharmacologically active catechol derivatives

Country Status (17)

Country Link
US (3) US5362733A (ko)
EP (1) EP0526598B1 (ko)
JP (1) JP2972377B2 (ko)
KR (1) KR100207144B1 (ko)
AT (1) ATE146462T1 (ko)
AU (1) AU646464B2 (ko)
CA (1) CA2080917C (ko)
DE (1) DE69123738T2 (ko)
FI (1) FI95129C (ko)
HU (1) HU214872B (ko)
IE (1) IE911430A1 (ko)
LT (1) LT3137B (ko)
LV (1) LV10097B (ko)
NO (1) NO301928B1 (ko)
PL (1) PL166269B1 (ko)
PT (1) PT97507B (ko)
WO (1) WO1991017151A1 (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022772A1 (en) * 1995-01-23 1996-08-01 Eli Lilly And Company Method for treating multiple sclerosis
AU5577498A (en) * 1997-01-31 1998-08-25 Shionogi & Co., Ltd. Compounds having metalloprotease inhibitory activity
EP1006794B1 (en) * 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
WO2001030771A1 (fr) * 1999-10-28 2001-05-03 Kyowa Hakko Kogyo Co., Ltd. Derives de thiazolidinedione
WO2002053155A1 (en) * 2000-12-30 2002-07-11 Geron Corporation Telomerase inhibitor
MXPA04000695A (es) * 2001-07-23 2005-08-26 Galileo Pharmaceuticals Inc Compuestos citoprotectores, formulaciones farmaceuticas y cosmeticas y metodos.
US6679051B1 (en) * 2002-07-31 2004-01-20 Ford Global Technologies, Llc Diesel engine system for use with emission control device
RU2379299C2 (ru) 2003-11-21 2010-01-20 Актелион Фармасьютиклз Лтд Производные 5-(бенз-(z)-илиден)тиазолидин-4-она и их применение в качестве иммуносупрессорных агентов
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
US7872027B2 (en) * 2006-02-17 2011-01-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Low molecular weight Myc-max inhibitors
DK2094676T3 (da) * 2006-11-23 2013-06-10 Actelion Pharmaceuticals Ltd Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
FR2919608B1 (fr) * 2007-08-01 2012-10-05 Univ Rennes Derives d'imidazolones,procede de preparation et applications biologiques
US20100075926A1 (en) * 2008-07-23 2010-03-25 Li-Huei Tsai Activation of histone deacetylase 1 (hdac1) protects against dna damage and increases neuronal survival
KR101411838B1 (ko) * 2011-02-09 2014-06-27 부산대학교 산학협력단 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
DK2734510T3 (en) 2011-07-22 2019-03-04 Massachusetts Inst Technology CLASS I-HISTONDEACETYLASES (HDAC) ACTIVATORS AND APPLICATIONS THEREOF
PT2885266T (pt) 2012-08-17 2020-05-29 Actelion Pharmaceuticals Ltd Processo para a preparação de (2z,5z)-5-(3-cloro-4-((r)-2,3-di-hidropropoxi)benzilideno)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona e intermediário utilizado no referido processo
WO2017176812A1 (en) * 2016-04-05 2017-10-12 Immune Sensor, Llc cGAS ANTAGONIST COMPOUNDS
JPWO2022163843A1 (ko) * 2021-02-01 2022-08-04

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1038050B (de) * 1955-11-17 1958-09-04 Farmaceutici Italia S A Soc Verfahren zur Herstellung von 5-(3', 4'-Dioxybenzyliden)-Derivaten heterocyclischer Verbindungen
US4013770A (en) * 1972-06-16 1977-03-22 Canada Packers Limited Antiviral 5-(substituted benzal) hydantoins
GB1434074A (en) * 1972-06-16 1976-04-28 Canada Packers Ltd Antiviral compositions comprising hydantoin derivatives
US4264617A (en) * 1972-06-16 1981-04-28 Canada Packers, Limited Antiviral 5-(substituted benzal) hydantoins
GB1601310A (en) * 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
DE3013626C2 (de) * 1980-04-09 1985-06-27 Degussa Ag, 6000 Frankfurt Verfahren zur Herstellung von 5-Arylidenhydantoinen (A)
DE3013647C2 (de) * 1980-04-09 1985-07-11 Degussa Ag, 6000 Frankfurt Verfahren zur Herstellung von 5-Arylidenhydantoinen (B)
JPS60233063A (ja) * 1984-05-02 1985-11-19 Showa Denko Kk ５−ベンジリデンヒダントインの製造法
US4582903A (en) * 1984-08-17 1986-04-15 Stauffer Chemical Company Synthesis of unsaturated hydantoins with an inexpensive catalyst
US4650876A (en) * 1984-08-17 1987-03-17 Stauffer Chemical Company Hydrogenation of substituted, unsaturated hydantoins to substituted, saturated hydantoins
PT83152B (pt) * 1985-08-09 1989-03-30 Lilly Co Eli Processo para a preparacao de compostos di-t-butilfenoicos
US5208250A (en) * 1988-05-25 1993-05-04 Warner-Lambert Company Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents
US5306822A (en) * 1988-05-25 1994-04-26 Warner-Lambert Company Arylmethylenyl derivatives of oxazolidinone
IE940525L (en) * 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
GB8911073D0 (en) * 1989-05-15 1989-06-28 Fujisawa Pharmaceutical Co New benzofuran derivatives,a process for the preparation thereof and pharmaceutical composition comprising the same
JPH1052765A (ja) 1996-08-09 1998-02-24 Sukematsu Iwashita 鉄筋材の圧接装置

Also Published As

Publication number Publication date
HUT65662A (en) 1994-07-28
FI95129C (fi) 1995-12-27
LV10097A (lv) 1994-05-10
PT97507A (pt) 1992-01-31
LT3137B (en) 1995-01-31
PL166269B1 (pl) 1995-04-28
NO301928B1 (no) 1997-12-29
KR100207144B1 (en) 1999-07-15
IE911430A1 (en) 1991-11-06
JP2972377B2 (ja) 1999-11-08
EP0526598A1 (en) 1993-02-10
PT97507B (pt) 1998-08-31
HU214872B (hu) 1998-07-28
US5362733A (en) 1994-11-08
NO924132L (no) 1992-12-23
LTIP227A (lt) 1994-08-25
FI924838A (fi) 1992-10-23
NO924132D0 (no) 1992-10-26
AU646464B2 (en) 1994-02-24
LV10097B (en) 1995-02-20
US5614541A (en) 1997-03-25
US5889037A (en) 1999-03-30
WO1991017151A1 (en) 1991-11-14
FI95129B (fi) 1995-09-15
CA2080917A1 (en) 1991-10-28
HU9203369D0 (en) 1993-01-28
CA2080917C (en) 2001-06-12
DE69123738T2 (de) 1997-07-03
EP0526598B1 (en) 1996-12-18
DE69123738D1 (en) 1997-01-30
ATE146462T1 (de) 1997-01-15
JPH05331148A (ja) 1993-12-14
FI924838A0 (fi) 1992-10-23
AU7761891A (en) 1991-11-27

Similar Documents

Publication Publication Date Title
KR930700468A (ko) 신규의 약학적 활성을 지닌 카테콜 유도체
RU2324684C2 (ru) Пиримидиновые производные
US7550617B2 (en) Compositions and methods for the treatment of renal and cardiovascular disease
KR950704330A (ko) 면역억제제로서의 라파마이신 카보네이트 에스테르(Rapamycin carbonate esters as immunosuppressant agents)
KR880002840A (ko) 이미다졸 화합물, 그의 제조 방법 및 이것으로 되는 제약 조성물
KR930700482A (ko) 신경보호성 안돌론 및 관련 유도체
KR930021624A (ko) 피리미딘 유도체 및 이의 제조방법
KR890011592A (ko) 기관내 허혈병의 치료용 조성물
HUT47268A (en) Process for production of dihydro-piridine-derivatives and medical compositions containing them as active substance
RU2000123169A (ru) Бензотиадиазолы и их производные
KR950701328A (ko) 메일라드 반응 억제제로서의 티아졸 또는 이미다졸 유도체(Thiazole or imidazole derivatives as Maillard reaction inhibitors)
KR910015562A (ko) 뇌부전 질환치료용 약제, 신규 2-(1-피페라지닐)-4-페닐시클로알카노 피리미딘 유도체, 및 그의 제법
IE83426B1 (en) New pharmacologically active catechol derivatives
CA2122509A1 (en) Potentiation of bioreductive agents
RU2005100761A (ru) Амидзамещенные производные ксантина, обладающие модуляторной активностью в отношении биосинтеза глюкозы из неуглеводных субстратов
RU2000132206A (ru) Применение производных бензофуроксана при лечении стенокардии
KR950702544A (ko) 비페닐메탄 유도체 및 이를 함유하는 약제
JP2818082B2 (ja) ベンゾチアゼピン誘導体
US4338334A (en) 1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and methods of treating rheumatoid arthritis and immune complex diseases
KR950703956A (ko) 순환 장애 개선제[circulatory disturbance ameliorant]
KR900701270A (ko) 피리디닐메틸(술피닐 또는 티오)벤즈이미다졸을 사용한 인체 눈의 녹내장 및 관련 장해의 치료 방법
US6184214B1 (en) Pharmaceutical formulations
KR870010043A (ko) 헤테로고리로 치환된 벤즈이미다졸, 그의 제조방법 및 이들을 함유하는 제약조성물
RU2096407C1 (ru) Производные катехола и способ их получения
KR900014339A (ko) 헤테로시클릭 화합물, 그의 제조방법, 이를 함유하는 제약 조성물 및 의약으로서의 용도

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20020411

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee